Efficacy of Ustekinumab for the treatment of perianal fistulizing Crohn's disease: a multicentre retrospective study.

Front Med (Lausanne) · 2026 · PMC13395751 · PMID 42500534

Europe PMC DOI

hedged sentence

0.0890

closest p · 1.8× alpha

0.0890

boldest claim

The sentences

did not reach statistical significancep = 0.089so close (0.05 < p ≤ 0.1)

Among biologic-experienced patients, those with only one prior biologic had better outcomes (58.6%) than those with two or more prior biologics (40.0%), although this difference did not reach statistical significance ( p = 0.089), likely due to limited sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.